MedTrace Logo

The Efficacy and Safety of Protoxin in Subjects With Moderate to Severe Glabellar Lines

NCT06124794 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 155

Last updated 2024-06-21

No results posted yet for this study

Summary

This clinical trial is an extended clinical trial for test subjects who participated in the phase 3 clinical trial of PT\_BTA\_P3\_21 (clinical trial plan number) and completed follow-up observation up to 16 weeks after administration of clinical trial drugs, and evaluates the effectiveness and safety of repeated administration of protoxin in those with moderate or severe brow wrinkles.

Conditions

  • Glabellar Frown Lines

Interventions

BIOLOGICAL

PROTOXIN

Clostridium botulinum toxin type A

Sponsors & Collaborators

  • Protox Inc.

    lead INDUSTRY

Principal Investigators

  • Beomjoon Kim, PI · Chung-Ang University Hosptial, Chung-Ang University College of Medicine

  • Yangone Lee, CI · Konkuk University Medical Center

  • Jonghoon Lee, PI · Nown Eulji Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-12-18
Primary Completion
2024-02-26
Completion
2024-06-14

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06124794 on ClinicalTrials.gov